Mineralys Therapeutics to Participate in Upcoming Investor Conferences
RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences.
| Guggenheim Healthcare Innovation Conference | |
| Date: | Tuesday, November 11, 2025 |
| Time: | 9:30am ET |
| Format: | Fireside Chat |
| Stifel Healthcare Conference | |
| Date: | Thursday, November 13, 2025 |
| Time: | 2:00pm ET |
| Format: | Fireside Chat |
| 8th Annual Evercore Healthcare Conference | |
| Date: | Wednesday December 3, 2025 |
| Time: | 3:25pm ET |
| Format: | Fireside Chat |
The live webcasts and archives of these fireside chats can also be accessed on the “” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit . Follow Mineralys on , and .
Contact:
Investor Relations
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email:
